drugset / Trial / NCT03550859

HMG-CoA Reductase add-on in Chronic Kidney Disease Patients With Proteinuria

NCT03550859

Phase 4 Unknown 374 enrolled Yuhan Corporation
RandomizedParallel-groupOpen-labelTreatment

Summary

This study is to evaluate the renal function of HMG-CoA reductase add-on in chronic kidney disease patients with proteinuria.

Timeline

Start
2018-06-05
Primary completion
2021-12
Completion
2021-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Rosuvastatin Small molecule 10 mg
Comparator Telmisartan Other / unclassified 40 mg